uniQure NV (QURE) Short Interest Update
uniQure NV (NASDAQ:QURE) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 874,899 shares, a decrease of 27.0% from the October 14th total of 1,198,353 shares. Based on an average daily trading volume, of 131,108 shares, the days-to-cover ratio is currently 6.7 days. Currently, 6.4% of the shares of the stock are sold short.
uniQure NV (NASDAQ:QURE) opened at 8.14 on Monday. uniQure NV has a 12 month low of $6.63 and a 12 month high of $22.79. The firm’s 50-day moving average is $7.36 and its 200-day moving average is $8.94. The company’s market capitalization is $204.55 million.
A number of equities research analysts have recently issued reports on the stock. Cowen and Company reissued a “buy” rating on shares of uniQure NV in a report on Thursday, July 28th. Jefferies Group set a $28.00 target price on shares of uniQure NV and gave the company a “buy” rating in a research note on Thursday, July 28th. Zacks Investment Research downgraded shares of uniQure NV from a “hold” rating to a “sell” rating in a research note on Thursday, August 4th. Chardan Capital reaffirmed a “buy” rating on shares of uniQure NV in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. set a $16.00 target price on shares of uniQure NV and gave the company a “buy” rating in a research note on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.10.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. increased its position in shares of uniQure NV by 105.7% in the second quarter. Point72 Asset Management L.P. now owns 562,447 shares of the company’s stock worth $4,145,000 after buying an additional 288,982 shares during the period. Spark Investment Management LLC boosted its position in uniQure NV by 28.5% in the second quarter. Spark Investment Management LLC now owns 380,400 shares of the company’s stock worth $2,803,000 after buying an additional 84,400 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in uniQure NV by 5.8% in the first quarter. UBS Asset Management Americas Inc. now owns 345,403 shares of the company’s stock worth $4,103,000 after buying an additional 18,803 shares in the last quarter. BlackRock Fund Advisors boosted its position in uniQure NV by 7.4% in the second quarter. BlackRock Fund Advisors now owns 315,775 shares of the company’s stock worth $2,327,000 after buying an additional 21,657 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in uniQure NV during the second quarter worth approximately $804,000. Institutional investors own 31.88% of the company’s stock.
uniQure NV Company Profile
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.